Dependence on government contract funding
A large share of current activity is tied to BARDA, MTEC, and DHA programs with milestone-based funding.
- Scope
- U.S. government research revenue
- Materiality
- high
Spectral AI, Inc.
Spectral AI, Inc. is a U.S.-based medical technology company focused on artificial intelligence for wound assessment and burn evaluation. Its core platform, DeepView System, combines imaging hardware with software intended to support clinical decision-making in healthcare and military settings through its operating company and related subsidiaries.
−43,4 %
45,4 %
−38,5 %
−33,6 %
0.94
0.90
| % | |
|---|---|
| DeepView System hardware | 35% Proprietary imaging device platform used to capture clinical images for AI analysis. |
| SaMD / software licensing | 25% Software licensing for DeepView System, including access to algorithm updates and hosting. |
| Government R&D contracts | 40% Applied research and development work tied to BARDA, MTEC, and DHA programs. |
Spectral AI sells primarily to government and defense-related research customers today, with BARDA, MTEC, and DHA...
- U.S. government research agenciesprimary
BARDA, MTEC, and DHA fund DeepView development for burn and battlefield applications.
- Military and defense medical usersprimary
Military healthcare programs use handheld burn evaluation tools in field and trauma settings.
- Hospitals and burn centerssecondary
Clinical sites would buy DeepView for wound and burn assessment and treatment support.
- Clinics and site-of-service providerssecondary
Outpatient and point-of-care settings would use the system for faster triage and workflow support.
The company is headquartered in the United States and its disclosed contract activity is centered on U.S...
- •United States is the core operating and contracting base
- •Government-funded development work is tied to U.S. agencies
- •Commercial pricing is planned by country and site of service
- •Future adoption could expand beyond the U.S. healthcare market
- •No country revenue breakdown was disclosed in the excerpts
Spectral AI’s strategy is to convert DeepView from a development-stage platform into a commercial product with both...
01
Commercialize DeepView Systemmedium-term
Moves the company from contract-funded development toward product sales and software licensing.
02
Advance burn indication validationshort-term
Clinical and military validation supports adoption and reimbursement discussions.
03
Expand healthcare AI IP portfoliomedium-term
Additional intellectual property can strengthen differentiation and optionality.
The business depends on successful clinical validation, regulatory acceptance, and eventual commercial adoption of a...
Clinical validation and adoption risk
DeepView must prove accuracy and utility before broad hospital and military adoption.
- Scope
- Burn and wound assessment market
- Materiality
- high
Early-stage commercialization risk
The company is still transitioning from development contracts to product revenue.
- Scope
- Future device and software sales
- Materiality
- high
Regulatory and reimbursement uncertainty
Medical software and imaging products may face approval, labeling, and reimbursement hurdles.
- Scope
- SaMD commercialization
- Materiality
- high
Revenue recognition on government contracts
Research and development revenue
Warrant liabilities
Other income/expense and net loss
Fair value of debt and stock-based compensation
Operating and non-operating results
Income tax valuation allowances
Tax provision and balance sheet
: 29.4.2026